Aptamers, sometimes termed "chemical antibodies," have been engineered into multimerized versions for therapeutic application. The groups of Gilboa and Sullenger now report the development of a bivalent aptamer-molecular device as a receptor agonist that has the same functional properties, but stronger avidity than a corresponding antibody. © 2008 Elsevier Ltd. All rights reserved.
Mendeley saves you time finding and organizing research
Choose a citation style from the tabs below